Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medi... (or the short- and long-term treatment of...)

HOME >> MEDICINE >> NEWS

Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds

Date:9/2/2007

or the short- and long-term treatment of schizophrenia, acute mixed and manic episodes of bipolar I disorder, and maintenance treatment of bipolar disorder. Since Zyprexa was introduced in 1996, it has been prescribed to approximately 20 million people worldwide.

Zyprexa is not approved for the treatment of patients with dementia- related psychosis. Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared with those patients taking a placebo. In addition, compared to elderly patients with dementia-related psychosis taking a placebo, there was a significantly higher incidence of cerebrovascular adverse events in elderly patients with dementia-related psychosis treated with Zyprexa.

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including Zyprexa.

As with all antipsychotic medications, a rare and potentially fatal condition known as NMS has been reported with Zyprexa. If signs and symptoms appear, immediate discontinuation is recommended. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize Tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

The most common treatment-emergent adverse event associated with Zyprexa in plac
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Effective And Economical Agent For Anthrax
6. New target for antidiabetic agents identified
7. Gold Nanoparticles: Agents For Noninvasive Cancer Therapy
8. A potent causative agent of dental flourosis: Fluoride
9. Another causative agent of adult onset asthma : Atopy
10. Revelation Of Cancer Agent Could Help In Developing Effective Cancer Drugs
11. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer

Post Your Comments:

Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medi...(or the short- and long-term treatment of...),Health